Mortality and Re-Hospitalization in Chronic Heart Failure in Mahasarakham hospital.
Keywords:
chronic heart failure, heart failure reduce ejection fraction, mortality, re-hospitalizationAbstract
Objective : A study of mortality and re-hospitalization in chronic heart failure (HF)
Methods : The data was retrospectively collected from January 1, 2017 to December 31, 2019 in the patients who were diagnosed with chronic HF with left ventricular ejection fraction (LVEF) less than 50% and were followed for at least 6 months, The primary outcomes were changes in patients’ characteristics, treatment pattern, rate of mortality and re-hospitalization during each calendar year.
Result : A total of 192 patients were enrolled, which 27 patients died (all-cause death) accounting for a mortality rate of 4.7% per year and 70 patients were re-hospitalized for chronic HF and the rate of re-hospitalization for chronic HF was at 12.1% per year. A yearly comparative study of baseline data such as gender, age, underlying disease, combination therapy (ACEI/ARB, beta-blocker, MRA), optimizing medication, as well as yearly rates of mortality and re-hospitalization from heart failure did not differ significantly. However, the duration of optimize medication was significantly shorten during the later years.
Conclusion : Mortality and rate of re-hospitalization of patients with chronic HF and LVEF <50% at Mahasarakam hospital was acceptable, which their rates were steady during the current years.
References
Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the heart failure association (HFA) of the ESC. 2016;37(27):2129–200. 2. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Colvin MM, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure. 2017;70(6):776–803. 3. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA Guideline for the Management of Heart Failure. 2013;62(16):e147–e239. 4. John R. Kapoor, Roger Kapoor, Christine Ju, Paul A. Heidenreich, et al. Precipitating Clinical Factors, Heart Failure Characterization, and Outcomes in Patients Hospitalized With Heart Failure With Reduced, Borderline, and Preserved Ejection Fraction. J Am Coll Cardiol HF 2016;4:464–472. 5. Buakhamsri A, MD¹, Chirakarnjanakorn S, MD², Sanguanwong S, MD³, et al. Heart Failure Council of Thailand (HFCT) 2019 Heart Failure Guideline: Pharmacologic Treatment of Chronic Heart Failure - Part I. J Med Assoc Thai 2019;102(2):240-244 6. Yancy CW, Lopatin M, Stevenson LW, et al. Clinical Presentation, Management, and In-Hospital Outcomes of Patients Admitted with Acute Decompensated Heart Failure With Preserved Systolic Function. J Am Coll Cardiol 2006;47:76– 84. 7. Bertram Pitt, Faiez Zannad, Willem Remme, et al. The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure. N Engl J Med 1999;341:709-717. 8. SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293–302. 9. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996;334:1349–1355. 10. กมลรัตน์ ทองปลั่ง. การดูแลผู้ป่วยหัวใจล้มเหลวเรื้อรังแบบสหสาขาวิชาชีพในคลินิกหัวใจล้มเหลวโรงพยาบาลนครปฐม. วารสารแพทย์เขต 4-5 2561;37(2):108-118.
Gaziano TA, Fonarow GC, Claggett B, et al. Cost- effectiveness analysis of sacubitril/valsartan vs enalapril in patients with heart failure and reduced ejection fraction. JAMA Cardiol. 2016; 1:666–72. 12. Okumura N, Jhund PS, Gong J, et al. Effects of sacubitril/valsartan in the PARADIGM-HF trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) according to back- ground therapy. Circ Heart Fail 2016;9:e003212. 13. M. Packer, S.D. Anker, J. Butler, et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart. N Engl J Med 2020;383:1413-1424. 14. Docherty KF, Jhund PS, Inzucchi SE, et al. Effects of dapagliflozin in DAPA-HF according to background heart failure therapy. Eur Heart J 2020;41:2379–2392. 15. Solomon SD, Jhund PS, Claggett BL, et al. Effect of dapagliflozin in patients with HFrEF treated with sacubitril/valsartan: the DAPA-HF trial. J Am Coll Cardiol HF 2020;8:811–818.
Neal M Dixit, MD, MBA, Shivani Shah, PharmD, APh, et al. Optimizing Guideline-directed Medical Therapies for Heart Failure with Reduced Ejection Fraction During Hospitalization. US Cardiology Review 2021;15:e07.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Mahasarakham Hospital Journal
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
วารสารนี้เป็นลิขสิทธิ์ของโรงพยาบาลมหาสารคาม
